Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

LENZ

LENZ Therapeutics Inc.

Last Close
Sep 06 • 04:00PM ET
23.80
Dollar change
-0.08
Percentage change
-0.34 		%
Held by: VTI VXF IWM IWN VTWO IWC AVSC VTWV RSSL IWV
IndexRUT P/E- EPS (ttm)-9.44 Insider Own19.80% Shs Outstand27.50M Perf Week7.69%
Market Cap654.50M Forward P/E- EPS next Y-2.57 Insider Trans23.40% Shs Float22.05M Perf Month2.63%
Income-72.31M PEG- EPS next Q-0.46 Inst Own71.65% Short Float9.54% Perf Quarter58.24%
Sales0.00M P/S- EPS this Y67.33% Inst Trans-2.52% Short Ratio12.30 Perf Half Y60.67%
Book/sh7.46 P/B3.19 EPS next Y3.69% ROA-29.53% Short Interest2.10M Perf Year126.52%
Cash/sh7.14 P/C3.34 EPS next 5Y25.90% ROE-34.67% 52W Range9.51 - 25.77 Perf YTD91.94%
Dividend Est.- P/FCF- EPS past 5Y-483.52% ROI-37.28% 52W High-7.64% Beta0.47
Dividend TTM- Quick Ratio23.23 Sales past 5Y0.00% Gross Margin- 52W Low150.18% ATR (14)1.31
Dividend Ex-DateMar 15, 2024 Current Ratio23.23 EPS Y/Y TTM41.13% Oper. Margin0.00% RSI (14)57.30 Volatility7.66% 5.61%
Employees6 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price33.80
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q94.13% Payout- Rel Volume0.73 Prev Close23.88
Sales Surprise- EPS Surprise16.44% Sales Q/Q- EarningsAug 14 AMC Avg Volume171.06K Price23.80
SMA203.84% SMA508.74% SMA20042.07% Trades Volume124,112 Change-0.34%
Date Action Analyst Rating Change Price Target Change
Aug-12-24Initiated H.C. Wainwright Buy $38
Apr-15-24Initiated William Blair Outperform
Apr-15-24Initiated Leerink Partners Outperform $32
Apr-10-24Initiated Citigroup Buy $34
Mar-27-24Initiated Piper Sandler Overweight $28
Feb-23-23Downgrade Cowen Outperform → Market Perform
Feb-23-23Downgrade Cantor Fitzgerald Overweight → Neutral $3
Feb-23-23Downgrade BofA Securities Neutral → Underperform $3 → $2
Jan-25-23Downgrade BTIG Research Buy → Neutral
Jan-18-23Downgrade BofA Securities Buy → Neutral $7 → $3
Show Previous Ratings
Aug-27-24 04:01PM
LENZ Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Aug-14-24 04:05PM
LENZ Therapeutics Reports Second Quarter 2024 Financial Results
(GlobeNewswire)
Aug-12-24 08:00AM
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
(GlobeNewswire)
Aug-07-24 04:01PM
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
(GlobeNewswire)
Jul-15-24 08:00AM
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
(GlobeNewswire)
08:00AM Loading…
Jun-10-24 08:00AM
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
(GlobeNewswire) +14.18%
May-30-24 08:00AM
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
(GlobeNewswire)
May-12-24 09:03AM
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2024 Earnings Call Transcript
(Insider Monkey)
May-08-24 04:01PM
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
(GlobeNewswire)
May-01-24 04:01PM
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
(GlobeNewswire)
Apr-03-24 07:00AM
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
(Business Wire)
Apr-02-24 04:01PM
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
(Business Wire)
Mar-21-24 04:30PM
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
(Business Wire) +7.64%
10:09AM
11 Stocks that Paid Special Dividends in 2024
(Insider Monkey)
Mar-08-24 05:00PM
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
(Business Wire) +18.79%
10:48AM Loading…
Mar-01-24 10:48AM
Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm
(GlobeNewswire)
Feb-02-24 11:58AM
Kuehn Law Encourages DSKE, RYZB, ROVR, and GRPH Investors to Contact Law Firm
(GlobeNewswire)
Jan-27-24 12:07PM
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates FNCB, PWFL, DOC, GRPH
(GlobeNewswire)
Nov-16-23 12:00PM
What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock
(Zacks)
Nov-15-23 07:00AM
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
(Business Wire)
Jun-23-23 07:00AM
Graphite Bio Announces Departure of Chief Financial Officer
(Business Wire)
May-15-23 07:44AM
Graphite Bio, Inc.'s (NASDAQ:GRPH) largest shareholders are private equity firms with 43% ownership, institutions own 22%
(Simply Wall St.) +6.02%
May-10-23 10:18AM
Should You Buy Graphite Bio (GRPH) Ahead of Earnings?
(Zacks)
Apr-26-23 02:10PM
12 Gene Editing Stocks With the Best Long-Term Potential
(Insider Monkey)
Mar-29-23 04:20PM
11 Most Promising Gene Editing Stocks According to Analysts
(Insider Monkey)
Mar-25-23 10:12AM
We're Keeping An Eye On Graphite Bio's (NASDAQ:GRPH) Cash Burn Rate
(Simply Wall St.)
Mar-20-23 04:05PM
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
(Business Wire)
Feb-23-23 05:36PM
Sickle-cell gene therapy developer stops program, cuts half of staff
(American City Business Journals) +15.91%
Feb-22-23 04:05PM
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
(Business Wire)
Jan-10-23 09:35AM
Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround
(Zacks)
05:54PM Loading…
Jan-06-23 05:54PM
Two Covid-era biotech IPOs Spruce and Graphite Bio see stock head in different directions
(American City Business Journals) -39.54%
09:07AM
Graphite Bio Shares Tank After Pausing Sickle Cell Therapy Study
(Benzinga)
Jan-05-23 05:57PM
Graphite Bio pauses early-stage blood disease therapy trial
(Reuters)
04:05PM
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
(Business Wire)
Dec-11-22 10:00AM
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
(Business Wire)
Nov-21-22 08:00AM
Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
(Business Wire)
Nov-17-22 09:45AM
2 Strong Buy Penny Stocks That Could See 200% Gains (Or More)
(TipRanks)
Nov-09-22 04:05PM
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
(Business Wire)
Nov-03-22 09:05AM
Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition
(Business Wire)
Oct-16-22 08:33AM
Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation
(Simply Wall St.)
Oct-11-22 08:00AM
Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention
(Business Wire)
Sep-06-22 08:00AM
Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference
(Business Wire)
Aug-30-22 05:47PM
Potential sickle cell disease 'cure' jumps to clinic, yet investors remain cool
(American City Business Journals)
Aug-11-22 04:05PM
Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results
(Business Wire) +5.03%
08:16AM
Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease
(Business Wire)
Jun-17-22 02:26PM
BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock
(Benzinga) +12.15%
Jun-01-22 08:00AM
Graphite Bio Announces Participation in Jefferies Healthcare Conference
(Business Wire)
May-29-22 02:15PM
I'm 'Following Up' on a Biotech Trade With Attractive Potential
(TheStreet.com)
May-16-22 06:00AM
Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting
(Business Wire)
May-12-22 04:05PM
Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results
(Business Wire) +14.04%
May-09-22 08:13AM
Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans
(Simply Wall St.) -19.44%
May-04-22 08:00AM
Graphite Bio Announces Participation in Upcoming Investor Conferences
(Business Wire) +6.22%
May-03-22 08:00AM
Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease
(Business Wire)
May-02-22 04:38PM
Graphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Presentation About Beta-thalassemia Program
(Business Wire)
Mar-28-22 08:00AM
Graphite Bio Announces Participation in H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference
(Business Wire)
Mar-23-22 12:28PM
Insiders who purchased Graphite Bio, Inc. (NASDAQ:GRPH) earlier this year lose an additional US$64k as the stock sinks to US$6.16
(Simply Wall St.) -8.60%
08:00AM
Graphite Bio Announces Formation of Scientific Advisory Board
(Business Wire)
Mar-21-22 08:25AM
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results
(Business Wire) -15.15%
Mar-03-22 08:00AM
Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference
(Business Wire)
Mar-02-22 08:00AM
Graphite Bio Appoints Alethia Young as Chief Financial Officer
(Business Wire)
Feb-08-22 10:20AM
Is a Surprise Coming for Graphite Bio (GRPH) This Earnings Season?
(Zacks)
Jan-27-22 08:00AM
Graphite Bio Announces Participation in Upcoming Investor Conferences
(Business Wire) -6.67%
Jan-26-22 06:30PM
Expanding gene editing firm Graphite Bio signs new lease in South San Francisco
(American City Business Journals)
Dec-11-21 09:00AM
Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition
(Business Wire)
Dec-07-21 08:00AM
Graphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell Disease
(Business Wire) +5.94%
Nov-17-21 08:00AM
Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease
(Business Wire)
Nov-10-21 04:05PM
Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results
(Business Wire)
Nov-04-21 09:13AM
Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and Exposition
(Business Wire)
Oct-21-21 08:00AM
Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit
(Business Wire)
Oct-18-21 11:00AM
10% Owner Of Graphite Bio Makes $670K Buy
(Benzinga)
04:37AM
3 Stocks Insiders Are Buying
(Benzinga)
Oct-12-21 01:00PM
Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease Association of America National Convention
(Business Wire)
Oct-05-21 08:00AM
Graphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National Convention
(Business Wire) -6.79%
Sep-25-21 10:12AM
We Think Graphite Bio (NASDAQ:GRPH) Can Afford To Drive Business Growth
(Simply Wall St.)
Aug-30-21 08:00AM
Graphite Bio Announces Participation in Upcoming September Investor Conferences
(Business Wire)
Aug-12-21 04:05PM
Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results
(Business Wire)
Jun-30-21 05:15PM
Graphite Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
(Business Wire) +11.34% -8.07%
Jun-24-21 09:08PM
Graphite Bio Announces Pricing of Upsized Initial Public Offering
(Business Wire)
LENZ Therapeutics, Inc. operates as a clinical stage company, which develops ophthalmic pharmaceutical products. It offers eye drop product treatment for presbyopia. The company was founded by James McCollum in July 2013 and is headquartered in Del Mar, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schimmelpennink Evert B.President, CEO and SecretaryJul 22 '24Option Exercise1.0445,00046,80045,000Jul 23 08:16 PM
Chevallard Daniel R.Chief Financial OfficerMay 14 '24Buy15.683,18849,9883,188May 15 04:13 PM
MCCOLLUM JAMES WDirectorMay 13 '24Buy15.9931,332501,093525,565May 14 05:29 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 21 '24Buy15.03998,00915,000,0753,319,339Mar 25 08:48 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

VIRX

Viracta Therapeutics Inc

Last Close
Sep 06 • 04:00PM ET
0.2410
Dollar change
+0.0070
Percentage change
2.99 		%
VIRX Viracta Therapeutics Inc daily Stock Chart
Held by: VTI VXF
Index- P/E- EPS (ttm)-1.16 Insider Own29.71% Shs Outstand39.09M Perf Week8.12%
Market Cap9.50M Forward P/E- EPS next Y-0.66 Insider Trans0.00% Shs Float27.71M Perf Month-46.40%
Income-45.34M PEG- EPS next Q-0.27 Inst Own21.80% Short Float9.15% Perf Quarter-62.04%
Sales0.00M P/S- EPS this Y32.07% Inst Trans3.11% Short Ratio4.20 Perf Half Y-70.25%
Book/sh-0.07 P/B- EPS next Y26.39% ROA-83.82% Short Interest2.54M Perf Year-82.91%
Cash/sh0.76 P/C0.32 EPS next 5Y- ROE-208.67% 52W Range0.20 - 1.46 Perf YTD-57.72%
Dividend Est.- P/FCF- EPS past 5Y44.96% ROI-1697.34% 52W High-83.49% Beta0.66
Dividend TTM- Quick Ratio1.08 Sales past 5Y134.94% Gross Margin- 52W Low19.31% ATR (14)0.04
Dividend Ex-Date- Current Ratio1.08 EPS Y/Y TTM15.69% Oper. Margin0.00% RSI (14)29.02 Volatility10.28% 15.38%
Employees40 Debt/Eq7.05 Sales Y/Y TTM- Profit Margin- Recom1.67 Target Price3.50
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q22.95% Payout- Rel Volume0.97 Prev Close0.23
Sales Surprise- EPS Surprise31.82% Sales Q/Q- EarningsAug 14 BMO Avg Volume604.01K Price0.24
SMA20-21.91% SMA50-43.26% SMA200-62.48% Trades Volume583,445 Change2.99%
Date Action Analyst Rating Change Price Target Change
Aug-16-24Downgrade Leerink Partners Outperform → Market Perform $5 → $3
Feb-01-22Initiated RBC Capital Mkts Outperform $10
May-03-21Initiated H.C. Wainwright Buy $35
Apr-26-21Initiated SVB Leerink Outperform $18
Mar-25-21Initiated Evercore ISI Outperform $45
Sep-03-24 07:00AM
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
(GlobeNewswire) +11.42%
Aug-14-24 07:05AM
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
(GlobeNewswire) -18.31%
07:00AM
Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan
(GlobeNewswire)
Jun-11-24 07:40AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
(InvestorPlace) +6.00%
Jun-07-24 07:22AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
(InvestorPlace)
04:05PM Loading…
May-17-24 04:05PM
Viracta Therapeutics Announces New Employment Inducement Grants
(GlobeNewswire)
May-14-24 07:00AM
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
(GlobeNewswire)
May-09-24 10:54PM
VIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q1 2024
(InvestorPlace) -7.88%
04:05PM
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
(GlobeNewswire)
May-08-24 06:00AM
3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck
(InvestorPlace)
May-07-24 04:05PM
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
(GlobeNewswire)
Apr-15-24 08:00AM
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
(GlobeNewswire) -32.17%
Apr-01-24 08:30AM
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
(GlobeNewswire) +8.82%
Mar-08-24 08:51AM
VIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023
(InvestorPlace)
Mar-07-24 04:05PM
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
(GlobeNewswire) -11.92%
08:00AM Loading…
Feb-29-24 08:00AM
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
(GlobeNewswire) -8.43%
Feb-06-24 04:05PM
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
(GlobeNewswire) -9.37%
Jan-17-24 08:00AM
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
(GlobeNewswire)
Jan-04-24 08:00AM
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
(GlobeNewswire)
Dec-12-23 08:00AM
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma
(GlobeNewswire) -6.28%
Dec-04-23 08:30AM
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
(GlobeNewswire)
Nov-09-23 08:30AM
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire) -14.70%
Nov-07-23 04:15PM
Viracta Therapeutics to Present at Upcoming Investor Conferences
(GlobeNewswire) +19.17%
Oct-04-23 07:00AM
Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers
(GlobeNewswire) -10.68%
Sep-05-23 09:00AM
Viracta Therapeutics to Host R&D Day on October 4, 2023
(GlobeNewswire)
Aug-18-23 04:05PM
Viracta Therapeutics Announces New Employment Inducement Grant
(GlobeNewswire)
Aug-14-23 08:00AM
Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Aug-08-23 08:30AM
Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
(GlobeNewswire)
Aug-07-23 07:30AM
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
(GlobeNewswire) -6.67%
Jun-28-23 08:00AM
Viracta Therapeutics Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
(GlobeNewswire) +5.59%
04:15PM Loading…
May-31-23 04:15PM
Viracta Therapeutics to Present at the Jefferies Healthcare Conference
(GlobeNewswire) +6.02%
May-17-23 09:50AM
2 Strong Buy Penny Stocks With Over 400% Upside on the Horizon
(TipRanks) +37.35%
May-11-23 04:05PM
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
(GlobeNewswire)
May-08-23 04:05PM
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates
(GlobeNewswire) -11.00% +20.22%
May-02-23 04:05PM
Viracta Therapeutics Announces Departure of Chief Medical Officer
(GlobeNewswire) -8.13%
Apr-19-23 04:30PM
Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
(GlobeNewswire)
Mar-13-23 04:05PM
Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
(GlobeNewswire)
Mar-08-23 04:05PM
Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference
(GlobeNewswire)
Feb-07-23 04:05PM
Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
(GlobeNewswire)
Jan-19-23 08:30AM
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma
(GlobeNewswire)
Jan-08-23 01:00PM
Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives
(GlobeNewswire)
Nov-30-22 06:10PM
Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress
(GlobeNewswire)
Nov-21-22 05:08PM
Viracta Therapeutics Announces New Employment Inducement Grant
(GlobeNewswire) -6.18%
Nov-14-22 04:41PM
Viracta Therapeutics Announces New Employment Inducement Grant
(GlobeNewswire)
Nov-10-22 04:05PM
Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs
(GlobeNewswire) -9.20%
Nov-02-22 04:05PM
Viracta Therapeutics to Present at Upcoming Investor Conferences
(GlobeNewswire)
Sep-19-22 04:30PM
Viracta Therapeutics Announces New Employment Inducement Grant
(GlobeNewswire) -8.44% -9.98%
08:00AM
Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth
(PR Newswire)
Sep-07-22 09:00AM
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma
(PR Newswire) +11.86%
Aug-16-22 04:15PM
Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases
(PR Newswire) -7.24%
Aug-11-22 09:00AM
Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors
(PR Newswire) +9.21%
Aug-09-22 08:30AM
Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
(PR Newswire) -12.15%
Aug-01-22 08:19AM
What Kind Of Shareholders Hold The Majority In Viracta Therapeutics, Inc.'s (NASDAQ:VIRX) Shares?
(Simply Wall St.)
Jun-13-22 04:15PM
Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award
(PR Newswire) -7.30% -5.51%
Jun-02-22 08:30AM
Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting
(PR Newswire)
Jun-01-22 04:15PM
Viracta Therapeutics to Present at the Jefferies Healthcare Conference
(PR Newswire)
May-23-22 08:00AM
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
(GlobeNewswire)
May-13-22 04:05PM
Viracta Therapeutics Announces New Employment Inducement Grant
(PR Newswire) +13.90%
May-11-22 04:05PM
Viracta Therapeutics to Present at Upcoming May Investor Conferences
(PR Newswire) -11.69% -6.37%
May-10-22 04:05PM
Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
(PR Newswire)
Apr-20-22 11:58AM
Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors
(PR Newswire)
Apr-07-22 10:13AM
Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
(PR Newswire)
Mar-18-22 04:10PM
Viracta Therapeutics Announces New Employment Inducement Grant
(PR Newswire) +6.43%
Mar-09-22 04:30PM
Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
(PR Newswire) +5.76%
Feb-22-22 11:35AM
What Type Of Shareholders Own The Most Number of Viracta Therapeutics, Inc. (NASDAQ:VIRX) Shares?
(Simply Wall St.)
Feb-10-22 09:00AM
Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
(PR Newswire) +9.12%
Feb-08-22 09:48AM
2 Strong Buy Penny Stocks That Could Rally to $10 (or More)
(TipRanks) +8.04%
Jan-31-22 08:30AM
Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors
(PR Newswire) +11.20%
Jan-04-22 09:00AM
Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
(PR Newswire) -6.39%
Dec-16-21 08:30AM
Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index
(PR Newswire)
Dec-13-21 07:15PM
Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presentations at ASH 2021
(PR Newswire) -9.05% -10.99%
11:30AM
Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021
(PR Newswire)
Nov-29-21 08:00AM
Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma
(PR Newswire) -5.58%
Nov-10-21 08:00AM
Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
(PR Newswire)
Nov-05-21 09:00AM
Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance
(PR Newswire)
Nov-04-21 09:00AM
Viracta Therapeutics Announces Upcoming Oral and Poster Presentations at the 2021 American Society of Hematology Annual Meeting
(PR Newswire)
Nov-01-21 04:05PM
Viracta Therapeutics to Present at Upcoming Investor Conferences
(PR Newswire)
Oct-06-21 08:00AM
Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors
(PR Newswire)
Sep-07-21 08:00AM
Viracta Therapeutics to Present at Upcoming Investor Conferences in September
(PR Newswire)
Aug-23-21 08:00AM
Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China
(PR Newswire) +6.95%
Aug-16-21 08:00AM
Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA, to its Board of Directors
(PR Newswire) -10.43%
Aug-12-21 08:00AM
Viracta Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
(PR Newswire)
Jul-21-21 08:00AM
Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors
(PR Newswire)
Jul-06-21 08:00AM
Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team
(PR Newswire) -6.02%
Jun-28-21 08:00AM
Viracta Therapeutics Announces its Addition to the Russell 2000® Index and other FTSE Russell Indexes
(PR Newswire)
Jun-01-21 08:00AM
Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma
(PR Newswire)
May-25-21 07:46AM
What Kind Of Shareholders Hold The Majority In Viracta Therapeutics, Inc.'s (NASDAQ:VIRX) Shares?
(Simply Wall St.) +6.23%
May-18-21 04:05PM
Viracta Therapeutics to Host Key Opinion Leader Webinar
(PR Newswire) +6.46%
May-12-21 04:05PM
Viracta Therapeutics Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
(PR Newswire) -16.65%
Apr-29-21 06:01AM
Analysts Bet on These 2 Biotech Stocks; See Over 50% Upside Potential
(TipRanks)
Apr-08-21 08:00AM
Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
(PR Newswire)
Mar-23-21 08:00AM
Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction
(PR Newswire) -5.09%
Mar-11-21 08:00AM
Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
(PR Newswire) +7.73%
Mar-04-21 08:00AM
Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team
(PR Newswire) -18.30%
Mar-03-21 08:00AM
Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference
(PR Newswire)
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pomerantz RogerDirectorMay 25 '24Option Exercise0.009,0350108,410May 29 07:12 PM
ROYSTON IVORDirectorMay 25 '24Option Exercise0.0025,2190789,303May 29 07:07 PM
ROYSTON IVORDirectorFeb 25 '24Option Exercise0.0025,2190764,084Feb 27 07:58 PM
Pomerantz RogerDirectorFeb 25 '24Option Exercise0.009,034099,375Feb 27 07:56 PM
Chevallard Daniel R.CFO and COOFeb 25 '24Option Exercise0.006,8890105,711Feb 27 07:54 PM
Chevallard Daniel R.CFO and COOFeb 27 '24Sale0.733,4052,493102,306Feb 27 07:54 PM
Rothera MarkPresident and CEONov 30 '23Buy0.4952,09425,73452,094Dec 04 04:54 PM
Rothera MarkPresident and CEODec 01 '23Buy0.4947,90623,627100,000Dec 04 04:54 PM
Chevallard Daniel R.CFO and COONov 25 '23Option Exercise0.006,8890102,542Nov 28 07:06 PM
Chevallard Daniel R.CFO and COONov 28 '23Sale0.503,7201,86098,822Nov 28 07:06 PM
ROYSTON IVORDirectorNov 25 '23Option Exercise0.0025,2190738,865Nov 28 07:03 PM
Pomerantz RogerDirectorNov 25 '23Option Exercise0.009,034090,341Nov 28 07:01 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.